Abstract
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. If left untreated, BCCs can become locally aggressive or even metastasize. Currently available treatments include local destruction, surgery, and radiation. Systemic options for advanced disease are limited. The Hedgehog (Hh) pathway is aberrantly activated in a majority of BCCs and in other cancers. Hh pathway inhibitors are targeted agents that inhibit the aberrant activation of the Hh pathway, with smoothened being a targeted component. Sonidegib is a novel smoothened inhibitor that was recently approved by the US Food and Drug Administration. This review focuses on BCC pathogenesis and the clinical efficacy of sonidegib for the treatment of advanced BCC.
Original language | English (US) |
---|---|
Pages (from-to) | 5671-5678 |
Number of pages | 8 |
Journal | OncoTargets and Therapy |
Volume | 9 |
DOIs | |
State | Published - Sep 14 2016 |
Keywords
- Clinical trials
- Hedgehog pathway
- Nonmelanoma skin cancer
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)